Convergence between Singapore and Korea
Global Campus for Innovative Ecosystem
Integrating the entire life cycle from discovery to production
Prestige Biopharma is establishing a global campus to accelerate its R&D efforts. The R&D center located in Biopolis, Singapore, serves as the headquarters and focuses on various tasks such as biosimilar research and development, CMC (Chemistry, Manufacturing, and Controls), and clinical research. The Singapore R&D center functions as the headquarter for advancing innovation and early-stage discoveries to the next phase, ultimately driving them towards successful commercialization. The center focuses on drug development activities such as preclinical development, CMC (Chemistry, Manufacturing, and Controls), and clinical research for both biosimilars and first-in-class biologics.
In Busan, South Korea, the Innovative Discovery Center (IDC) is dedicated to the development of key first-in-class therapies, with a focus on antibody-based treatments and antibody platforms. Additionally, IDC is engaged in the development of diagnostic devices utilizing major mechanisms like PAUF.
Furthermore, IDC is actively involved in research and development for diverse platforms and modalities, as well as new drug development ecosystem through open innovation. The global campus connecting Singapore and South Korea fosters collaboration with major bio-clusters and open innovation from various countries and regions. This endeavor aims to create an ecosystem that contributes to innovation in human life.
Innovation through synergistic collaboration
Singapore and Korea’s research institutes are operating a robust collaborative system. Singapore focuses on CMC (Chemistry, Manufacturing, and Controls), preclinical and clinical bioanalysis, and clinical studies. On the other hand, Korea’s Innovative Discovery Center (IDC) is responsible for the discovery and development of antibody-based therapeutics. Through the specialized research and services of our global campuses, we are embarking on a journey towards ‘Innovation for Life’ together.
In addition, we are conducting business related to approvals and sales in each region through our branches located in key countries.
An ecosystem for accelerating the supply of biopharmaceuticals
Furthermore, as a subsidiary of Prestige Biopharma Group, Prestige Biologics is accelerating the production of biopharmaceuticals. With accumulated experience in diverse antibody biopharmaceutical production, we also offer CDMO (Contract Development and Manufacturing Organization) services to collaborate on supplying biopharmaceuticals to global customers. We are building a complete cycle of pharmaceuticals, from discovery to production, within our ecosystem.